(Boston) - Research conducted by a pair of physicians at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) has led to the development of a test that can help diagnose ...
Daniel C. Cattran, MD The MENTOR study is poised to change first-line-treatment recommendations for idiopathic membranous nephropathy. The Membranous Nephropathy Trial of Rituximab (MENTOR) study is ...
Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN) There are currently no therapies ...
No therapies currently exist that can halt the progression of chronic kidney disease in children or restore the ability of kidney cells to filter blood. Recently, researchers at the GOFARR Laboratory ...
Fenofibrate Found Safe in Diabetes With Renal Impairment For patients with idiopathic membranous nephropathy (IMN) and persistent nephrotic syndrome, rituximab treatment is associated with good rates ...
Thrombospondin type-1 domain-containing 7A (THSD7A) is the most recently recognized target antigen in patients with membranous nephropathy. We stained membranous nephropathy biopsies processed in our ...
Effective therapy of post-transplant membranous nephropathy may improve outcomes. Membranous nephropathy (MN) recurs after kidney transplantation in nearly a third of patients with a history of MN but ...
Rituximab (Rituxan, Genentech) should replace cyclosporine for the treatment of primary membranous nephropathy, say editorialists commenting on the results of the Membranous Nephropathy Trial of ...
While air pollution is known to cause respiratory and cardiovascular diseases, a new study indicates that it also likely causes damage to the kidneys. While air pollution is known to cause respiratory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback